Risk of infection in patients with lymphoma receiving rituximab: systematic review and meta-analysis
Open Access
- 12 April 2011
- journal article
- review article
- Published by Springer Nature in BMC Medicine
- Vol. 9 (1) , 36
Abstract
The addition of Rituximab (R) to standard chemotherapy (C) has been reported to improve the end of treatment outcome in patients affected by CD-20 positive malignant lymphomas (CD20+ ML). Nevertheless, given the profound and prolonged immunosuppression produced by R there are concerns that severe infections may arise. A systematic review and meta-analysis were performed to determine whether or not the addition of R to C may increase the risk of severe infections in adults undergoing induction therapy for CD20+ ML.Keywords
This publication has 41 references indexed in Scilit:
- Incidence of hematologic malignancies in Europe by morphologic subtype: results of the HAEMACARE projectBlood, 2010
- A systematic review and meta-analysis of immunochemotherapy with rituximab for B-cell non-Hodgkin's lymphomaActa Oncologica, 2010
- Classification of lymphoid neoplasms: the microscope as a tool for disease discoveryBlood, 2008
- Pseudo‐bowel obstruction due to varicella zoster virus infection after autologous stem cell transplantationAmerican Journal of Hematology, 2008
- Hepatitis B virus-related liver disease in isolated anti-hepatitis B-core positive lymphoma patients receiving chemo- or chemo-immune therapyHaematologica, 2008
- Granulocyte-Macrophage Colony-Stimulating Factor Potentiates Rituximab in Patients With Relapsed Follicular Lymphoma: Results of a Phase II StudyJournal of Clinical Oncology, 2008
- Persistent and Relapsing Babesiosis in Immunocompromised PatientsClinical Infectious Diseases, 2008
- Molecular Evidence of Persistent Echovirus 13 Meningoencephalitis in a Patient with Relapsed Lymphoma after an Outbreak of Meningitis in 2000Journal of Clinical Microbiology, 2003
- Enteroviral Meningoencephalitis after Anti‐CD20 (Rituximab) TreatmentClinical Infectious Diseases, 2003
- Prophylaxis of hepatitis B reactivation using lamivudine in a patient receiving rituximabAmerican Journal of Hematology, 2001